AST-201 (Aston Sci)

AST-201 is an investigational, intradermally administered plasmid DNA therapeutic cancer vaccine developed by Aston Sci for ovarian cancer. The pUMVC3-based construct encodes N-terminal epitopes of human insulin-like growth factor-binding protein 2, inducing IGFBP2-specific type 1 helper T-cell, memory T-cell, and cytotoxic T-cell immune responses against IGFBP2-expressing tumor cells. Aston Sci's CornerStone-004 program is a randomized Phase 2 study in newly diagnosed homologous-recombination proficient Stage III ovarian cancer after debulking surgery, evaluating AST-201 with rhuGM-CSF and adjuvant paclitaxel plus carboplatin; the sponsor describes the Phase 2 IND as approved and the study as site-ready but not opened. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-igfbp2-plasmid-dna-vaccine-ast-201))

Other names

pUMVC3-hIGFBP-2pUMVC-3-hIGFBP-2pUMVC 3-hIGFBP-2pUMVC3-hIGFBP2pUMVC-3-hIGFBP2pUMVC 3-hIGFBP2anti-IGFBP2 plasmid DNA vaccineanti-IGFBP-2 plasmid DNA vaccineanti-IGFBP 2 plasmid DNA vaccine